Physician profile
Mark E Merrell
NPI 1922342377
$1,250.95
in general payments reported to CMS, 2019-2025
19 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2022: $205 · 2023: $396 · 2024: $72.78 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $351.38 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $227.68 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Corcept Therapeutics | $151.19 | 2023-2025 | Korlym |
| Mylan Specialty L.P. | $90.27 | 2021-2022 | |
| Exact Sciences Corporation | $54.37 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.35 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $43.91 | 2021-2022 | |
| Abbvie INC. | $41.02 | 2021-2024 | |
| Axsome Therapeutics, INC. | $38.08 | 2025 | Symbravo, Auvelity |
| Medtronic, INC. | $28.91 | 2022 | |
| Insulet Corporation | $27.98 | 2025 | Omnipod |
| Vertex Pharmaceuticals Incorporated | $24.78 | 2025 | |
| Astellas Pharma US INC | $23.15 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.11 | 2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $19.22 | 2025 | Eliquis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.05 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $16.72 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $14.98 | 2025 | Trelegy Ellipta |
| Corium, LLC | $8.80 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Merrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.